BNTC vs QURE vs SRPT vs RCKT

For growth investors, Sarepta Therapeutics, Inc.

(SRPT) is the stronger pick with 15. 6% revenue growth year-over-year, versus -40. 6% for uniQure N. V. (QURE). Analysts rate Benitec Biopharma Inc. (BNTC) a "Buy" — based on 7 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, uniQure N.

V. (QURE) delivered a total return of -25. 8%, compared to -91. 6% for Rocket Pharmaceuticals, Inc. (RCKT). Over 10 years, the gap is even starker: QURE returned +86. 3% versus BNTC's -97. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), uniQure N.

V. (QURE) is the lower-risk stock at 1. 26β versus Sarepta Therapeutics, Inc. 's 2. 02β — meaning SRPT is approximately 61% more volatile than QURE relative to the S&P 500. On balance sheet safety, Benitec Biopharma Inc. (BNTC) carries a lower debt/equity ratio of 1% versus 3% for uniQure N. V. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Sarepta Therapeutics, Inc.

(SRPT) is pulling ahead at 15. 6% versus -40. 6% for uniQure N. V. (QURE). On earnings-per-share growth, the picture is similar: Benitec Biopharma Inc. grew EPS 60. 8% year-over-year, compared to -404. 7% for Sarepta Therapeutics, Inc.. Over a 3-year CAGR, SRPT leads at 33. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Rocket Pharmaceuticals, Inc.

(RCKT) is the more profitable company, earning 0. 0% net margin versus -91. 5% for Benitec Biopharma Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: RCKT leads at 0. 0% versus -99. 9% for BNTC. At the gross margin level — before operating expenses — QURE leads at 89. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for BNTC: 122.

4% to $27. 00.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, uniQure N.

V. (QURE) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 26)). Sarepta Therapeutics, Inc. (SRPT) carries a higher beta of 2. 02 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (QURE: +86. 3%, SRPT: +18. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: BNTC is a small-cap quality compounder stock; QURE is a small-cap quality compounder stock; SRPT is a small-cap high-growth stock; RCKT is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.